Picture of Cambridge Cognition Holdings logo

COG Cambridge Cognition Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
TechnologySpeculativeMicro CapSucker Stock

REG - Cambridge Cognition - Senior Management Appointments

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220406:nRSF3951Ha&default-theme=true

RNS Number : 3951H  Cambridge Cognition Holdings PLC  06 April 2022

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Senior Management Appointments

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce two senior
management appointments.

 

Stephen Symonds has joined the Company as its new Chief Financial Officer and
is expected to join the board in due course.  Stephen is an experienced
finance professional and was until recently the Chief Financial Officer of
Envigo, a private equity backed provider of pre-clinical services for the
pharmaceutical industry, where he spent eight years.  Prior to that, Stephen
spent a decade with KPMG, working on a wide-ranging portfolio of clients.
 Earlier in his career, he built a broad experience in a variety of small to
medium-size accounting companies and as the finance lead in a family-owned
business.

 

The board would like to thank Nick Walters for providing the Company with
interim financial leadership while the Chief Financial Officer recruitment
process was conducted.

 

Francesca Cormack has been appointed as the Company's Chief Scientist, having
spent seven years at Cambridge Cognition, most recently as Director of
Research and Innovation.  Francesca will lead the Company's research and
development activities and act as the Company's scientific leader, with a view
to enhancing its competitive position and supporting its long-term business
success.  She is also an honorary senior research fellow at Cambridge
University's department of psychiatry.

 

Jenny Barnett, currently Chief Scientific Officer, will be stepping down from
the Company at the end of April 2022 to focus her efforts on Monument
Therapeutics.  Monument Therapeutics was spun out from Cambridge Cognition in
July 2021 and continues to work closely with the Company using its cognitive
assessments as core elements of their developments.

 

For further information, contact:

 Cambridge Cognition Holdings Plc             Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer       press@camcog.com (mailto:press@camcog.com)

 Steven Powell, Chairman
 Panmure Gordon (NOMAD and Joint Broker)      Tel: 020 7886 2500

 Freddy Crossley / Emma Earl / Mark Rogers    (Corporate Advisory)

 Rupert Dearden                               (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)       Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)       Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEANLSELDAEFA

Recent news on Cambridge Cognition Holdings

See all news